Israel’s Pitango Venture Capital is launching a fund that will reach $150 million to invest in health technology.
Flow, a medical device company, launched a medication-free treatment for depression comprising a brain stimulation headset and therapy app.
LabTwin’s AI-powered Digital Assistant Now Talks Back and Connects Data Sources in the Lab with New Open API
LabTwin GmbH, the world’s first voice and AI-powered digital lab assistant, announced the company’s new open API that will connect scientists with data sources both inside and outside of the lab.
With an opioid molecule awaiting regulatory review, Nektar Therapeutics announced the launch of Inheris Biopharma, which will be responsible for the commercialization of NKTR-181.
ElevateBio, a new company focused on the development of startup cell and gene therapy companies, launched with a $150 million Series A financing round.
Alphabet’s venture capital arm GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.
The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.
Start Codon launched in Cambridge, England with funding from keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, Jonathan Milner and Ian Tomlinson.
Vivek Ramaswamy’s Roivant Sciences has launched another “vant” company, this time in China, in a partnership with Hong Kong-based Sinovant Sciences.
Mylan NV shares slid 10 percent after the generic drug maker predicted poor 2019 earnings that led some Wall Street analysts to wonder if the company’s finances would worsen further.